Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Amortization of Deferred Charges (2010 - 2016)

Grifols' (GRFS) quarterly Amortization of Deferred Charges came in at $4.6 billion in Q4 2016, up 9.06% YoY from $4.3 billion in Q1 2016, and up 7253.3% on a QoQ basis from $63.2 million in Q3 2016.

Grifols (GRFS) Amortization of Deferred Charges (2010 - 2016) Analysis & Trends

Grifols (GRFS) has 7 years of Amortization of Deferred Charges data on file, last reported at $4.6 billion in Q4 2016.

  • Quarterly Amortization of Deferred Charges rose 9.06% year-over-year to $4.6 billion in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.7 billion (up 4.56% YoY) and the FY2016 annual result came in at $4.8 billion, up 10.34% from the prior year.
  • Amortization of Deferred Charges rose to $4.6 billion in Q4 2016, from $63.2 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $4.6 billion in Q4 2016 to a low of -$4.2 billion in Q2 2016.
  • A 5-year average of $1.5 billion and a median of $1.6 billion in 2012 frame the typical range for Amortization of Deferred Charges.
  • Annual changes were most pronounced in 2014 — Amortization of Deferred Charges jumped 638.69% — and 2016, when it sank 8932.49%.
  • Tracing GRFS's Amortization of Deferred Charges over 5 years: stood at $2.9 billion in 2012, then advanced by 11.66% to $3.3 billion in 2013, then rose by 16.75% to $3.8 billion in 2014, then grew by 11.29% to $4.3 billion in 2015, then increased by 9.06% to $4.6 billion in 2016.
  • The last three Amortization of Deferred Charges figures came in at $4.6 billion (Q4 2016), $63.2 million (Q3 2016), and -$4.2 billion (Q2 2016), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Grifols 5.45 Bn 4.45 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2016 4.64 Bn
Dec 31, 2016 4.64 Bn
Sep 30, 2016 63.16 Mn
Sep 30, 2016 63.16 Mn
Jun 30, 2016 -4.17 Bn
Jun 30, 2016 -4.17 Bn
Mar 31, 2016 4.20 Bn
Mar 31, 2016 4.20 Bn
Dec 31, 2015 4.26 Bn
Dec 31, 2015 4.26 Bn
Sep 30, 2015 -3.88 Bn
Sep 30, 2015 -3.88 Bn
Jun 30, 2015 -46.13 Mn
Jun 30, 2015 -46.13 Mn
Mar 31, 2015 4.21 Bn
Mar 31, 2015 4.21 Bn
Dec 31, 2014 3.83 Bn
Dec 31, 2014 3.83 Bn
Sep 30, 2014 289.18 Mn
Sep 30, 2014 289.18 Mn